mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment
Molecular Pharmaceutics · 02.11.2026 · 23 (11) · 5412-5425
DOI: 10.1021/acs.molpharmaceut.6c00483 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 08.10.2026. Verfasst von Remant Kc und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Material Engineering, Faculty of Engineering, University of Alberta, EdmontonAB T6G 2G6, Canada. Hauptthemen laut MEDLINE: TNF-Related Apoptosis-Inducing Ligand, Lung Neoplasms, RNA, Messenger, Polymers. Die Arbeit nennt 59 Literaturangaben. Gefördert von: Cancer Research Institute of Northern Alberta, Women and Children's Health Research Institute, CIHR.
Abstract (Originalsprache)
Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) has long been identified as a promising therapeutic due to its ability to induce apoptosis selectively in cancer cells. However, poor stability and rapid clearance of the administered TRAIL protein in circulation have hampered its clinical development. With recent advances in the mRNA technology, this study explored the potential of a lung cancer therapy by delivering TRAIL mRNA using lipopolymers. Here, we show that a leading cationic lipopolymer (mRNA-Fect) can package mRNA into nanoparticles (ζ-potential +14.9 to −8.6 mV with a 200−400 nm diameter, as observed by DLS measurement), thereby enhancing transfection efficiency in lung cancer cells. When tested with an mRNA encoding the reporter GFP gene (m-GFP), the lipopolymer induced GFP expression as early as 4 hours, reaching optimal expression by 24 hours, with a high transfection efficiency in lung cancer cells (GFP-positive population: 50−80%). Delivering an m-TRAIL led to TRAIL protein secretion as early as 2 hours post-transfection, significantly reducing viability (∼80%) and activating caspase-3/-7 in lung cancer cells. The lipopolymer successfully expressed reporter genes following intramuscular, subcutaneous, and intravenous administration in animal models. Furthermore, delivery of m-TRAIL suppressed tumor growth in a local lung cancer xenograft model, demonstrating therapeutic potential in the absence of any adverse effects. We conclude that mRNA-Fect-formulated m-TRAIL could be a potent therapy of lung cancers, showing promise for broader therapeutic applications in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Material Engineering, Faculty of Engineering, University of Alberta, EdmontonAB T6G 2G6, Canada.
- Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta, EdmontonAB T6G 2G6, Canada.
ORCID-Profile: Remant Kc, Mohammad Nasrullah, Hasan Uludağ
Förderung
- Cancer Research Institute of Northern Alberta
- Women and Children's Health Research Institute
- CIHR
- Natural Sciences and Engineering Research Council of Canada
- Mitacs
- Canadian Institutes of Health Research
Zitieren
APA
Kc, R., Nasrullah, M., Meenakshi Sundaram, D. N., Patel, D., Sandhu, G., Kucharski, C., & Uludağ, H. (2026). mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment. Molecular Pharmaceutics, 23(11), 5412-5425. https://doi.org/10.1021/acs.molpharmaceut.6c00483
Vancouver
Kc R, Nasrullah M, Meenakshi Sundaram DN, Patel D, Sandhu G, Kucharski C, et al. mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment. Molecular Pharmaceutics. 2026;23(11):5412-5425. doi:10.1021/acs.molpharmaceut.6c00483
BibTeX
@article{Kc2026,
author = {Kc, Remant and Nasrullah, Mohammad and Meenakshi Sundaram, Daniel Nisakar and Patel, Dev and Sandhu, Gurkirat and Kucharski, Cezary and Uludağ, Hasan},
title = {mRNA Delivery with Lipopolymers to Rejuvenate TRAIL Therapy for Lung Cancer Treatment},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {11},
pages = {5412--5425},
doi = {10.1021/acs.molpharmaceut.6c00483}
}
EUVIMED